Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
| ▸ | WIZ | O95785 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30275734 | 1.00 | CRBN (0.44) | CRBNDDB1PDE3BPDE3ABRD9 | |
| SCHEMBL26147996 | 0.94 | BRD9 (0.42) | CRBNDDB1PDE3BPDE3ABRD9 | |
| SCHEMBL30275748 | 0.94 | BRD9 (0.42) | CRBNDDB1PDE3BPDE3ABRD9 | |
| SCHEMBL30241705 | 0.88 | CRBN (0.41) | CRBNDDB1PDE3BPDE3ABRD9 | |
| SCHEMBL26147998 | 0.85 | CRBN (0.58) | CRBNDDB1 | |
| SCHEMBL30275730 | 0.85 | CRBN (0.58) | CRBNDDB1 | |
| SCHEMBL24773134 | 0.84 | CRBN (0.44) | CRBNDDB1BRD9WIZ | |
| SCHEMBL30919542 | 0.84 | CRBN (0.57) | CRBNDDB1 | |
| SCHEMBL30919857 | 0.82 | CRBN (0.55) | CRBNDDB1WIZ | |
| SCHEMBL27091258 | 0.82 | CRBN (0.55) | CRBNDDB1WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115666575-A | Compound and use thereof | 福宏治疗公司 | 2023-01-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885DDB1 987/4885PDE3B 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.